Search | Clinical Trials Finder

Conditions: Healthy Volunteers
Interventions: CC-11050; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Laryngopharyngeal Reflux, Cough, Throat Clearing, Dysphonia, Reflux
Interventions: Omeprazole 40 MG, Laryngeal Recalibration Therapy, GERD Lifestyle Recommendations; Drug · Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 89 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: San Deigo, California

Conditions: Non-erosive Reflux Disease
Interventions: Esomeprazole, Placebo; Drug
Lead sponsor: Midwest Biomedical Research; Other
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2020
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Exocrine Pancreatic Insufficiency, Chronic Pancreatitis, Pancreatectomy
Interventions: Viokase® 16, Placebo, Proton pump inhibitor (PPI), Omeprazole; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Osteoporosis, Hypomagnesemia
Interventions: EffCaMgCit, Placebo; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 99 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Asthma, Lung Diseases, Lung Diseases, Obstructive
Interventions: Esomeprazole, Placebo proton pump inhibitor; Drug
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 18 Years and older
Enrollment: 403 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 20
States / cities: Birmingham, Alabama • San Diego, California • Denver, Colorado + 17 more

Conditions: Heartburn
Interventions: Esomeprazole 20 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 2
States / cities: Oklahoma City, Oklahoma

Conditions: Nutritional Status
Interventions: GSK1325756; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Heartburn
Interventions: Lanzoprazole; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 28
States / cities: Hoover, Alabama • Huntsville, Alabama • Sierra Vista, Arizona + 23 more

Conditions: Otitis Media With Effusion
Interventions: lansoprazole, placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 2 Years to 12 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Dysphonia
Interventions: Lansoprazole, Placebo; Drug · Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 3 Years to 18 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Gastroesophageal Reflux Disease
Interventions: arbaclofen placarbil-Cohort 1, Placebo-Cohort 5, arbaclofen placarbil-Cohort 2, arbaclofen placarbil-Cohort 3, arbaclofen placarbil-Cohort 4, PPI; Drug
Lead sponsor: XenoPort, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 62
States / cities: Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: IW-3718, placebo, Standard-dose PPIs QD; Drug
Lead sponsor: Ironwood Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 93
States / cities: Anniston, Alabama • Mobile, Alabama • Phoenix, Arizona + 81 more

Conditions: GERD
Interventions: Nissen fundoplication, baclofen, Desipramine; Device · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 64 Years
Enrollment: 366 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 15
States / cities: Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 12 more

Conditions: Gastroesophageal Reflux Disease
Interventions: Standard dose (once daily) PPI plus low-dose antidepressant, Double dose PPI plus evening placebo, Rabeprazole , placebo, placebo; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Postoperative Nausea and Vomiting
Interventions: pantoprazole, Placebo; Drug
Lead sponsor: United States Naval Medical Center, Portsmouth; Federal
Eligibility: 18 Years to 79 Years · Female only
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Portsmouth, Virginia

Conditions: Gastroesophageal Reflux
Interventions: ADX10059, ADX10059 Matching Placebo; Drug
Lead sponsor: Addex Pharma S.A.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 28
States / cities: Little Rock, Arizona • Tucson, Arizona • Anaheim, California + 23 more

Conditions: Pancreatic Insufficiency, Cystic Fibrosis
Interventions: Omeprazole 20mg Capsule, Placebo oral capsule; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 12 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Gastroesophageal Reflux Disease, Heartburn
Interventions: Amiloride, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 59 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Osteoporosis, Hypomagnesemia
Interventions: EffCaMgCit, Placebo; Drug · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years to 99 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Amyotrophic Lateral Sclerosis
Interventions: GDC-0134, Placebo, Rabeprazole, Midazolam, Caffeine; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: San Francisco, California • Jacksonville, Florida • Miami, Florida + 5 more

Conditions: Wounds and Injuries, Rib Fractures
Interventions: Ketamine, Placebo, Intercostal Nerve Block, Acetaminophen, Ibuprofen, Pantoprazole, Methocarbamol, Opioid; Drug · Procedure
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Frequent Heartburn
Interventions: Lansoprazole, placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 852 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Parsippany, New Jersey

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: AST-120, Celphere CP-305; Drug
Lead sponsor: Ocera Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Tucson, Arizona

Search by objective public record fields.

A Study to Evaluate the Safety, Tolerability Pharmacokinetics, and Pharmacodynamics of a New Spray Dried Dispersion (SDD) Formulation of CC-11050 After Single Dose of CC-11050 and to Evaluate the Pharmacokinetics of CC-11050 Under Fasted and Fed Conditions and After Coadministration With Omeprazole

The Mechanism Versus PPI Trial

Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study

Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea

Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate

Study of Acid Reflux in Asthma

Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment

Pharmacokinetics and Safety of GSK1325756 in Elderly Subjects and Adult Subjects of in the Fed and Fasted States and in the Presence of a Proton Pump Inhibitors

Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn

A Clinical Trial of Proton Pump Inhibitors to Treat Children With Chronic Otitis Media With Effusion

Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric Hoarseness

A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)

A Trial of IW-3718 for 8 Weeks in Patients With Persistent Gastroesophageal Reflux Disease (GERD) Receiving Proton Pump Inhibitors (PPIs)

A Randomized Trial of Medical and Surgical Treatments for Patients With GERD Symptoms That Are Refractory to Proton Pump Inhibitors

Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)

Preoperative Use of Pantoprazole for Prevention of Post Operative Nausea and Vomiting in Gynecologic Surgery

ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD)

Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)

Do Acid Sensing Ion Channels Contribute to Heartburn?

EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy

A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis

Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients

Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn

Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI